Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05803421 · ClinicalTrials.gov registry record · Phase 3
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
A Phase 3 study of Obesity and Cardiovascular Diseases, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 2,749
- Enrollment target
- 20
- Study locations
NCT05803421 is a Phase 3 study of Obesity and Cardiovascular Diseases that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 2,749 participants, above the 816-participant average among 1,053 other Obesity trials with a reported enrollment target (237% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT05803421, a Phase 3 study of Obesity and Cardiovascular Diseases, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,749 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.
Conditions Studied
Interventions
- DRUG Orforglipron
- DRUG Insulin Glargine
Study Locations (20)
Arizona
- The Institute for Liver Health - Chandler
- Aventiv Research - Mesa
- Arizona Liver Health - Peoria - Peoria
- Elite Clinical Studies, LLC - Phoenix
- Absolute Clinical Research - Phoenix
- Clinical Research Institute of Arizona (CRI) - Sun City West - Sun City West
- Alliance for Multispecialty Research, LLC - Tempe
- Orange Grove Family Practice - Tucson
California
- Hope Clinical Research, Inc. - Canoga Park
- Valley Clinical Trials, Inc. - Covina
- Neighborhood Healthcare Institute of Health - Escondido
- Valley Research - Fresno
- Orange County Research Center - Lake Forest
- Ark Clinical Research - Long Beach
- Pacific Clinical Studies - Los Alamitos
Alabama
- Alliance for Multispecialty Research, LLC - Daphne
- Alliance for Multispecialty Research, LLC - Mobile
- Cahaba Research - Pelham - Pelham
- Syed Research Consultants Llc - Sheffield
Arkansas
- KLR Business Group, Inc. dba Arkansas Clinical Research - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,749 participants |
| Start Date | 2023-04-03 |
| Est. Completion | 2026-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05803421
The ClinicalTrials.gov registry entry for NCT05803421 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 2,749 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 816-participant average among 1,053 other Obesity trials with a reported enrollment target (237% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Orforglipron is the first listed.
NCT05803421 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Arizona, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT05803421 about?
NCT05803421 is a clinical study titled "A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk". The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.
What is the current status of trial NCT05803421?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 2,749 participants. The study started on 2023-04-03. Estimated completion is 2026-03.
What conditions does trial NCT05803421 study?
This clinical trial studies the following conditions: Obesity, Cardiovascular Diseases, Type 2 Diabetes, Overweight, Chronic Kidney Disease.
What interventions are being tested in trial NCT05803421?
The interventions under investigation include: Orforglipron (DRUG), Insulin Glargine (DRUG).
Who is sponsoring clinical trial NCT05803421?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05803421 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.